The approvals expand the use of Keytruda and Keytruda Qlex alongside Padcev into the perioperative treatment setting for adults with muscle-invasive bladder cancer.

The FDA has approved Sarclisa Escena, a subcutaneous on-body injector formulation of Sanofi’s multiple myeloma therapy isatuximab, becoming the first cancer treatment authorised in the US for delivery through an on-body injector system. Sanofi has secured US Food and Drug Administration (FDA) approval for Sarclisa Escena, a new subcutaneous (SC) formulation of its multiple myeloma therapy Sarclisa (isatuximab-irfc) delivered through an on-body injector (OBI). The approval rep

The new funding will accelerate manufacturing and commercial deployment of the FDA-cleared Marie system, which reimagines proton therapy by rotating the patient instead of the treatment machine.

Genentech has secured global rights to a fragment-based drug discovery programme targeting a key regulator of breast cancer cell growth.

The Medscape Oncologist Compensation Report 2026 paints a different picture from many other specialties.

Jazz Pharmaceuticals has expanded its oncology pipeline through a new collaboration with AbCellera, signing a deal worth more than $2.4 billion.

The US Food and Drug Administration (FDA) has approved a combination regimen of Merck & Co.’s Keytruda (pembrolizumab) and Welireg (belzutifan).

GSK has agreed to acquire Nuvalent in a $10.6bn all-cash transaction, bringing a trio of late-stage lung cancer assets into its oncology portfolio and marking one of the company’s largest strategic moves in over a decade.

Daraxonrasib, KRAS G12D, and the ASCO26 Signal That Broke a Long Silence

The approval introduces the first immunotherapy combination for BCG-naïve high-risk non-muscle-invasive bladder cancer, marking a potential shift in the standard of care.

The partnership expands a global co-development model spanning ADCs, multispecific antibodies, and early-stage oncology assets across US and China markets.

The move comes just days after a multi-billion dollar partnership with Regeneron, signalling strong investor appetite for next-generation intracellular targeting platforms.

Landmark decision ties bladder cancer treatment to molecular residual disease testing

Securing a next-generation JAK2 inhibitor strengthens Lilly’s position in rare blood cancers as pharma accelerates investment in mechanism-driven oncology assets.

Keytruda now approved across EU for PD-L1-positive platinum-resistant ovarian, fallopian tube, and primary peritoneal carcinoma.

The collaboration leverages Trialing’s platform to connect physicians with early-phase cancer studies and provide real-time updates on patient enrolment opportunities.

Wearable TTFields device now authorised in combination with chemotherapy following Phase III PANOVA-3 trial demonstrating overall survival benefit.